Summary

KEY FINDINGS
The North America botulinum toxin market is assessed to rise with a 10.10% CAGR during the forecasted period, 2023 to 2032. Market growth drivers include increasing demand for cosmetic procedures and expanding therapeutic uses in the region.
MARKET INSIGHTS
The North America botulinum toxin market growth assessment includes a thorough analysis of the United States and Canada. Canada’s growing interest in non-invasive cosmetic procedures has driven the use of botulinum neurotoxin injections for medical and cosmetic purposes. Three forms of botulinum toxin are available for patients, and Canada has 530 plastic surgeons contributing to the market, according to ISAPS. However, regulatory guidelines and associated side effects may hinder market growth.
Furthermore, the relatively high cost of products and treatments in Canada compared to emerging economies in Asia may result in patients traveling to the region for treatment. Canada also lags behind other developed and developing countries in terms of the number of esthetic surgeons and professionals, accounting for only 1% of the total number of plastic surgeons globally.
Despite these challenges, the growing demand for non-invasive cosmetic procedures, such as botulinum toxin injections, is expected to drive market growth. The Canadian government’s commitment to regulating cosmetic procedures and ensuring patient safety will also contribute to the growth of the market.
COMPETITIVE INSIGHTS
Leading market players operating in the market include AbbVie Inc, Revance Therapeutics Inc, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.4.1. IMPACT OF COVID-19 ON BOTULINUM TOXIN MARKET
2.5. MAJOR MARKET FINDINGS
2.5.1. FAVORABLE REGULATORY APPROVALS ADD TO MARKET GROWTH
2.5.2. GROWING AWARENESS ABOUT ‘NOTOX’
2.5.3. INFLATING COSMETIC TOURISM ADDS TO THE DEMAND FOR BOTULINUM TOXIN
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. SURGE IN DEMAND FOR AESTHETIC PROCEDURES
3.1.2. RISING GERIATRIC POPULATION
3.1.3. GROWING DEMAND FOR NON-INVASIVE COSMETIC PROCEDURES
3.2. KEY RESTRAINTS
3.2.1. CONCERNS REGARDING THE ADVERSE EFFECTS OF BOTULINUM TOXIN
3.2.2. LACK OF REIMBURSEMENT POLICIES SUPPORTING COSMETIC PROCEDURES
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.2. PORTER’S FIVE FORCES ANALYSIS
4.2.1. BUYERS POWER
4.2.2. SUPPLIERS POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING
4.3.1. GROWTH PROSPECT MAPPING FOR UNITED STATES
4.4. MARKET MATURITY ANALYSIS
4.5. MARKET CONCENTRATION ANALYSIS
5. MARKET BY TYPE
5.1. TYPE A BOTULINUM TOXIN
5.2. TYPE B BOTULINUM TOXIN
6. MARKET BY USER DEMOGRAPHIC
6.1. WOMEN
6.2. MEN
7. MARKET BY APPLICATION
7.1. MEDICAL
7.1.1. CHRONIC MIGRAINE
7.1.2. MUSCLE SPASM
7.1.3. OVERACTIVE BLADDER
7.1.4. HYPERHIDROSIS
7.1.5. OTHER MEDICAL APPLICATIONS
7.2. AESTHETIC
7.2.1. CROW’S FEET
7.2.2. FOREHEAD LINES
7.2.3. FROWN LINES/GLABELLAR
7.2.4. SQUARE JAW/MASSETER
7.2.5. OTHER AESTHETIC APPLICATIONS
8. MARKET BY END-USER
8.1. SPECIALTY AND DERMATOLOGY CLINICS
8.2. HOSPITALS AND CLINICS
8.3. OTHER END-USERS
9. GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1. MARKET SIZE & ESTIMATES
9.1.2. NORTH AMERICA BOTULINUM TOXIN MARKET DRIVERS
9.1.3. NORTH AMERICA BOTULINUM TOXIN MARKET CHALLENGES
9.1.4. NORTH AMERICA BOTULINUM TOXIN MARKET REGULATORY FRAMEWORK
9.1.5. KEY PLAYERS IN NORTH AMERICA BOTULINUM TOXIN MARKET
9.1.6. COUNTRY ANALYSIS
9.1.6.1. UNITED STATES
9.1.6.1.1. UNITED STATES BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.1.6.2. CANADA
9.1.6.2.1. CANADA BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
10. COMPETITIVE LANDSCAPE
10.1. KEY STRATEGIC DEVELOPMENTS
10.1.1. ACQUISITIONS
10.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
10.1.3. PARTNERSHIPS
10.1.4. BUSINESS EXPANSIONS
10.2. COMPANY PROFILES
10.2.1. ABBVIE
10.2.1.1. COMPANY OVERVIEW
10.2.1.2. PRODUCT LIST
10.2.1.3. STRENGTHS & CHALLENGES
10.2.2. CANDELA MEDICAL
10.2.2.1. COMPANY OVERVIEW
10.2.2.2. PRODUCT LIST
10.2.2.3. STRENGTHS & CHALLENGES
10.2.3. DAEWOONG PHARMACEUTICAL CO LTD
10.2.3.1. COMPANY PROFILE
10.2.3.2. PRODUCT LIST
10.2.3.3. STRENGTHS & CHALLENGES
10.2.4. EVOLUS INC
10.2.4.1. COMPANY OVERVIEW
10.2.4.2. PRODUCT LIST
10.2.4.3. STRENGTHS & CHALLENGES
10.2.5. GALDERMA
10.2.5.1. COMPANY OVERVIEW
10.2.5.2. PRODUCT LIST
10.2.5.3. STRENGTHS & CHALLENGES
10.2.6. HUGEL INC
10.2.6.1. COMPANY OVERVIEW
10.2.6.2. PRODUCT LIST
10.2.6.3. STRENGTHS & CHALLENGES
10.2.7. IPSEN
10.2.7.1. COMPANY OVERVIEW
10.2.7.2. PRODUCTS / SERVICES LIST
10.2.7.3. STRENGTHS & CHALLENGES
10.2.8. LANZHOU INSTITUTE OF BIOLOGICAL PRODUCTS CO LTD
10.2.8.1. COMPANY OVERVIEW
10.2.8.2. PRODUCT LIST
10.2.8.3. STRENGTHS & CHALLENGES
10.2.9. MEDYTOX INC
10.2.9.1. COMPANY OVERVIEW
10.2.9.2. PRODUCT LIST
10.2.9.3. STRENGTHS & CHALLENGES
10.2.10. MERZ PHARMA
10.2.10.1. COMPANY OVERVIEW
10.2.10.2. PRODUCT LIST
10.2.10.3. STRENGTHS & CHALLENGES
10.2.11. REVANCE THERAPEUTICS INC
10.2.11.1. COMPANY OVERVIEW
10.2.11.2. PRODUCT LIST
10.2.12. US WORLDMEDS LLC
10.2.12.1. COMPANY OVERVIEW
10.2.12.2. PRODUCT LIST